Impax Asset Management Group plc Sells 92,216 Shares of Bristol-Myers Squibb (NYSE:BMY)

Impax Asset Management Group plc reduced its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 33.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 185,850 shares of the biopharmaceutical company's stock after selling 92,216 shares during the quarter. Impax Asset Management Group plc's holdings in Bristol-Myers Squibb were worth $9,536,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BMY. OFI Invest Asset Management acquired a new stake in shares of Bristol-Myers Squibb during the third quarter worth $25,000. True Wealth Design LLC purchased a new stake in Bristol-Myers Squibb during the 4th quarter worth about $26,000. Milestone Investment Advisors LLC purchased a new stake in Bristol-Myers Squibb during the 3rd quarter worth about $27,000. Coppell Advisory Solutions LLC acquired a new stake in Bristol-Myers Squibb in the 2nd quarter worth about $28,000. Finally, Blue Bell Private Wealth Management LLC boosted its stake in Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 200 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded down $1.17 during trading on Thursday, reaching $49.12. The stock had a trading volume of 11,738,419 shares, compared to its average volume of 16,065,917. Bristol-Myers Squibb has a one year low of $47.58 and a one year high of $70.93. The stock has a market cap of $99.55 billion, a PE ratio of 12.81, a P/E/G ratio of 1.54 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. The firm's 50 day moving average price is $51.28 and its two-hundred day moving average price is $51.94.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the previous year, the company posted $1.82 earnings per share. The company's revenue for the quarter was up .6% compared to the same quarter last year. On average, research analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.89%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently 62.18%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Bank of America lowered Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Wells Fargo & Company reduced their price target on Bristol-Myers Squibb from $58.00 to $51.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 6th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Redburn Atlantic downgraded Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Finally, StockNews.com upgraded Bristol-Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $61.12.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.